ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Mizuho Markets Americas LLC

Mizuho Markets Americas LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 11.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 201,994 shares of the specialty pharmaceutical company’s stock after acquiring an additional 21,416 shares during the quarter. Mizuho Markets Americas LLC owned approximately 0.90% of ANI Pharmaceuticals worth $15,945,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Hantz Financial Services Inc. boosted its position in shares of ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 237 shares during the last quarter. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals in the first quarter valued at about $28,000. State of Wyoming acquired a new position in ANI Pharmaceuticals in the second quarter valued at about $50,000. Federated Hermes Inc. acquired a new position in ANI Pharmaceuticals in the third quarter valued at about $93,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in ANI Pharmaceuticals by 30.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock valued at $86,000 after buying an additional 253 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

Insider Activity

In related news, SVP Ori Gutwerg sold 2,772 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $79.50, for a total transaction of $220,374.00. Following the sale, the senior vice president directly owned 78,696 shares in the company, valued at approximately $6,256,332. This represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Thomas Andrew Rowland sold 459 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $79.21, for a total transaction of $36,357.39. Following the sale, the senior vice president owned 38,271 shares in the company, valued at $3,031,445.91. The trade was a 1.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 91,427 shares of company stock valued at $7,089,066. 8.10% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ:ANIP opened at $82.72 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The firm has a market capitalization of $1.88 billion, a PE ratio of 20.94 and a beta of 0.46. The firm’s 50-day moving average is $77.90 and its two-hundred day moving average is $80.11. ANI Pharmaceuticals, Inc. has a 1 year low of $56.71 and a 1 year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same period in the prior year, the firm earned $1.70 earnings per share. The business’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts predict that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.